Cas:89901-03-1 Methyl 4′-bromo-4-biphenylcarboxylate manufacturer & supplier

Chemical Name:Methyl 4′-bromo-4-biphenylcarboxylate

CAS.NO:89901-03-1

Synonyms:Methyl 4′-bromo-4-biphenylcarboxylate;methyl 4′-bromobiphenyl-4-carboxylate;[1,1′-Biphenyl]-4-carboxylic acid, 4′-bromo-, methyl ester;methyl 4′-bromo[1,1′-biphenyl]-4-carboxylate;4-bromobiphenyl-4-carboxylic acid methyl ester;methyl 4-(4′-bromophenyl)benzoate;[1,1′-Biphenyl]-4-carboxylicacid,4′-bromo-,methyl ester;4′-Brom-biphenyl-4-carbonsaeure-methylester

Molecular Formula:C₁₄H₁₁BrO₂

Molecular Weight:291.140

HS Code:2916399090

Physical and Chemical Properties:

Melting point:146-148ºC

Boiling point:382.7±25.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.588

PSA:26.30000

Exact Mass:289.994232

LogP:4.75

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3077 9 / PGIII

Packing Group:

Contact us for information like Methyl 4′-bromo-4-biphenylcarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4′-Brom-biphenyl-4-carbonsaeure-methylester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 4′-bromo[1,1′-biphenyl]-4-carboxylate Use and application,methyl 4′-bromobiphenyl-4-carboxylate technical grade,usp/ep/jp grade.

Related News: Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. Methyl 4′-bromo-4-biphenylcarboxylate manufacturer Rates of breast cancer-related genetic mutations in Black and white women are the same, according to a new study that contradicts previous research. Methyl 4′-bromo-4-biphenylcarboxylate supplier Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. Methyl 4′-bromo-4-biphenylcarboxylate vendor China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition. Methyl 4′-bromo-4-biphenylcarboxylate factory Rates of breast cancer-related genetic mutations in Black and white women are the same, according to a new study that contradicts previous research.